G6PD and cancer: Interestingly, the clinically relevant inhibitor of glycolysis, 2DG, was found to cause less severe cancer cell cytotoxicity (relative to glucose deprivation), presumably because 2DG can only partially inhibit the pentose cycle since it is still a substrate for G6PD [9], [15].